Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Webinars
  4. ESMO Virtual Journal Club - Webinar Series

ESMO Virtual Journal Club: July 2024

Aired live on 10 Jul 2024

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Presentation

83 slides, 70 min

Download slides

Programme

  • 10 July 2024
Welcome and introduction
Domenica Lorusso
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Alexandra Leary
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Thomas Yau
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Shani Paluch Shimon
Live Q&A and Discussion
All speakers

Description and DOIs

This ESMO Virtual Journal Club Webinar focused on three newly published studies, with an aim to enhance understanding and application of the latest research in the field.

This webinar aimed to discuss and evaluate notable recent publications on the topics of ovarian cancer, hepatocellular carcinoma and HR+ advanced breast cancer:

Pujade-Lauraine E, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023;34(12):1152-1164. doi:10.1016/j.annonc.2023.09.3110

Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835-1847. doi:10.1016/S0140-6736(23)01796-8

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131

Learning objectives

  • To discuss and critically evaluate notable recent publications.
  • To enhance the understanding and application of the latest research in the field.
  • To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
  • To identify and highlight any unclear aspects or unmet needs.

You may also be interested in...

ESMO Virtual Journal Club

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.